Save the date!
4th October 2022, 09:15-15:15 GMT
UK NEQAS LI Webinar: Best practice and standardisation of measurable residual disease testing in leukaemia
UK NEQAS for Leucocyte Immunophenotyping (UK NEQAS LI) are excited to announce an online webinar on the 4th October 2022 – 09:15-1515. The webinar will cover measurable residual disease (MRD) testing, the need for standardisation, with a particular focus on the rapidly developing application of MRD to acute myeloid leukaemia (AML). Please find further details in the PDF attached.
Further information on how to register for the event will be disseminated shortly.
UK NEQAS LI are currently seeking participants for a study assessing the use of DNA based next generation sequencing (NGS) to detect and quantify measurable residual disease in B-lymphoid malignancies using the immunoglobulin genes. Please find details of the study attached. We hope, if successful, this study will lead to the establishment of an ongoing external quality assessment/ proficiency testing programme. The study is open to participants using any NGS platform and DNA based commercial assay or in-house approach. There will be no charge to participants to take part in this study; however, participants will need to cover their own reagent costs.
This Flow Cytometry Course is aimed at both clinical applications and applications in cell biology and is open to all and is suitable for those who are relatively new to flow cytometry and who wish to expand their experience with applications and specific analysis.
Running from 12th - 16th September 2022
UK NEQAS LI has recently assessed the implementation of the National Institute for Health and Care Excellence (NICE) haematological cancers improving outcomes guidelines (NG47) across
UK NEQAS LI was recently part of an international harmonized study for data analysis in the evaluation of multiple myeloma residual disease by high sensitivity flow cytometry. Read about the findings here:
Read the latest publication from UK NEQAS LI that has assessed the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in AML:
As part of the continuous development of our EQA/PT provision we will be introducing a number of updates to our flow cytometry and molecular haematology programmes in 2022-2023.
The re-registration period for the 2022-2023 year opens on the 1st February 2022.
Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS accredited proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.
You can find our schedule of accreditation here.
Also a link to the UKAS website can be found here, where you will be able to view and download a PDF of our current accreditation certificate.
UK NEQAS for Leucocyte Immunophenotyping (UK NEQAS LI) now has a Facebook page and a Twitter account. We will be posting important messages to these accounts relating to our schemes so please like or follow us, respectively.
We hope that these feeds will act as a useful eductational resource for participants and collaborators alike, collating interesting papers, conference info, videos and news stories in haemato-oncology. As we develop our online presence we hope to publish some of our own educational content. If you have any feedback or ideas as to content you would like us to include, please do not hesitate to get in touch.